CA2143070A1 - Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge - Google Patents
Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolongeInfo
- Publication number
- CA2143070A1 CA2143070A1 CA 2143070 CA2143070A CA2143070A1 CA 2143070 A1 CA2143070 A1 CA 2143070A1 CA 2143070 CA2143070 CA 2143070 CA 2143070 A CA2143070 A CA 2143070A CA 2143070 A1 CA2143070 A1 CA 2143070A1
- Authority
- CA
- Canada
- Prior art keywords
- oil
- liquid suspension
- cellulose
- combinations
- controlled release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006194 liquid suspension Substances 0.000 title abstract 4
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003963 antioxidant agent Substances 0.000 abstract 3
- 235000006708 antioxidants Nutrition 0.000 abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 3
- -1 hydroxypropyl-ethyl Chemical group 0.000 abstract 3
- 239000003381 stabilizer Substances 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 2
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 2
- 229920002472 Starch Polymers 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 230000000648 anti-parkinson Effects 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 239000000939 antiparkinson agent Substances 0.000 abstract 2
- 229920001400 block copolymer Polymers 0.000 abstract 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 abstract 2
- 239000008157 edible vegetable oil Substances 0.000 abstract 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003921 oil Substances 0.000 abstract 2
- 235000019198 oils Nutrition 0.000 abstract 2
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 2
- 239000008107 starch Substances 0.000 abstract 2
- 235000019698 starch Nutrition 0.000 abstract 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 abstract 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004380 Cholic acid Substances 0.000 abstract 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- 239000001828 Gelatine Substances 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- SGXDXUYKISDCAZ-UHFFFAOYSA-N N,N-diethylglycine Chemical compound CCN(CC)CC(O)=O SGXDXUYKISDCAZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005642 Oleic acid Substances 0.000 abstract 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920002873 Polyethylenimine Polymers 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 235000019486 Sunflower oil Nutrition 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 229920002988 biodegradable polymer Polymers 0.000 abstract 1
- 239000004621 biodegradable polymer Substances 0.000 abstract 1
- 229960004205 carbidopa Drugs 0.000 abstract 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 239000002327 cardiovascular agent Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 229920002301 cellulose acetate Polymers 0.000 abstract 1
- 235000019416 cholic acid Nutrition 0.000 abstract 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract 1
- 229960002471 cholic acid Drugs 0.000 abstract 1
- 239000003240 coconut oil Substances 0.000 abstract 1
- 235000019864 coconut oil Nutrition 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 229960003964 deoxycholic acid Drugs 0.000 abstract 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 229960002216 methylparaben Drugs 0.000 abstract 1
- 239000002480 mineral oil Substances 0.000 abstract 1
- 235000010446 mineral oil Nutrition 0.000 abstract 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
- 229960002969 oleic acid Drugs 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 239000002600 sunflower oil Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 235000010384 tocopherol Nutrition 0.000 abstract 1
- 229960001295 tocopherol Drugs 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract 1
- 239000008158 vegetable oil Substances 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19993394A | 1994-02-22 | 1994-02-22 | |
| US08/199,933 | 1994-02-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2143070A1 true CA2143070A1 (fr) | 1995-08-23 |
| CA2143070C CA2143070C (fr) | 2001-12-18 |
Family
ID=22739620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2143070 Expired - Lifetime CA2143070C (fr) | 1994-02-22 | 1995-02-21 | Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2143070C (fr) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997003670A1 (fr) * | 1995-07-20 | 1997-02-06 | Smithkline Beecham P.L.C. | Compositions de paroxetine a liberation controlee |
| US5874447A (en) * | 1997-06-10 | 1999-02-23 | Synthon B. V. | 4-Phenylpiperidine compounds for treating depression |
| WO2000021521A2 (fr) * | 1998-10-13 | 2000-04-20 | Pfizer Products Inc. | Concentre de sertraline par voie orale |
| US6063927A (en) * | 1998-07-02 | 2000-05-16 | Smithkline Beecham Plc | Paroxetine derivatives |
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US9901561B2 (en) | 2015-05-06 | 2018-02-27 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| RU2678839C2 (ru) * | 2009-05-19 | 2019-02-04 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| US10624839B2 (en) | 2014-03-13 | 2020-04-21 | Neuroderm, Ltd. | Dopa decarboxylase inhibitor compositions |
| US10813902B2 (en) | 2014-03-13 | 2020-10-27 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103622942A (zh) * | 2013-11-04 | 2014-03-12 | 江苏大学 | 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法 |
-
1995
- 1995-02-21 CA CA 2143070 patent/CA2143070C/fr not_active Expired - Lifetime
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997003670A1 (fr) * | 1995-07-20 | 1997-02-06 | Smithkline Beecham P.L.C. | Compositions de paroxetine a liberation controlee |
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US7229640B2 (en) | 1995-07-20 | 2007-06-12 | Smithkline Beecham P.L.C. | Paroxetine controlled release compositions |
| EP1382337A1 (fr) * | 1995-07-20 | 2004-01-21 | Smithkline Beecham Plc | Nouvelle composition pharmaceutique de paroxétine |
| US6900327B2 (en) | 1997-06-10 | 2005-05-31 | Synthon Bct Technologies, Llc | 4-phenylpiperidine compounds |
| US5874447A (en) * | 1997-06-10 | 1999-02-23 | Synthon B. V. | 4-Phenylpiperidine compounds for treating depression |
| US7598271B1 (en) | 1997-06-10 | 2009-10-06 | Noven Therapeutics, Llc | Crystalline paroxetine methane sulfonate |
| US6063927A (en) * | 1998-07-02 | 2000-05-16 | Smithkline Beecham Plc | Paroxetine derivatives |
| US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
| AU766202B2 (en) * | 1998-10-13 | 2003-10-09 | Pfizer Products Inc. | Sertraline oral concentrate |
| WO2000021521A3 (fr) * | 1998-10-13 | 2000-07-20 | Pfizer Prod Inc | Concentre de sertraline par voie orale |
| WO2000021521A2 (fr) * | 1998-10-13 | 2000-04-20 | Pfizer Products Inc. | Concentre de sertraline par voie orale |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| RU2678839C2 (ru) * | 2009-05-19 | 2019-02-04 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| US10624839B2 (en) | 2014-03-13 | 2020-04-21 | Neuroderm, Ltd. | Dopa decarboxylase inhibitor compositions |
| US10813902B2 (en) | 2014-03-13 | 2020-10-27 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| CN107847722A (zh) * | 2015-05-06 | 2018-03-27 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| US10300033B2 (en) | 2015-05-06 | 2019-05-28 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US10328044B2 (en) | 2015-05-06 | 2019-06-25 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US10588882B2 (en) | 2015-05-06 | 2020-03-17 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| EP3291872A4 (fr) * | 2015-05-06 | 2019-02-13 | SynAgile Corporation | Suspensions pharmaceutiques contenant des particules de médicament, dispositifs pour leur administration, et leurs procédés d'utilisation |
| US10786474B2 (en) | 2015-05-06 | 2020-09-29 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US9901561B2 (en) | 2015-05-06 | 2018-02-27 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US11135191B2 (en) | 2015-05-06 | 2021-10-05 | Synagile Corporation | Devices for the administration of pharmaceutical suspensions |
| US11426376B2 (en) | 2015-05-06 | 2022-08-30 | Synagile Corporation | Devices for the administration of pharmaceutical suspensions |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11458115B2 (en) | 2020-11-17 | 2022-10-04 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2143070C (fr) | 2001-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2143070A1 (fr) | Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge | |
| KR100249469B1 (ko) | 연 젤라틴 캡슐 껍질 조성물 | |
| KR100666016B1 (ko) | 테스토스테론 운데카노에이트 및 피마자유를 포함하는 제제 | |
| ES2236245T3 (es) | Composiciones de prostaglandina para el tratamiento de la disfuncion erectil masculina. | |
| KR930008955B1 (ko) | 비타민류, 식이요법용 보충물등을 함유하는 연질젤용 에탄올 충전제제 | |
| ZA836582B (en) | Constant release rate solid oral dosage formulations of drugs having a pka7-10 and an aqueous solubility of 15-100g/ml water | |
| CA1312549C (fr) | Capsule de nifedipine a liberation instantanee, administree par voie buccale | |
| KR910000655B1 (ko) | 신규 형태의 연질캡슐 제조방법 | |
| KR880007051A (ko) | 틀니 안정용 조성물 | |
| RU2008105830A (ru) | Невыплевываемая, быстро распадающаяся пленка для орального применения, содержащая нейролептик | |
| DK0904064T3 (da) | Orale farmaceutiske præparater indeholdende kønshormoner | |
| EP0374359A3 (fr) | Capsule de gélatine molle à mâcher et à ingérer | |
| RU2002135623A (ru) | Рецептура на основе гепарина, глюкозаминогликана или гепариноида и применение рецептуры и ее основы | |
| EP0966966A3 (fr) | Forme posologique de néfadozone | |
| JP2003508434A5 (fr) | ||
| CA2298764A1 (fr) | Capsules rigides remplies d'une preparation pharmaceutique | |
| IT1263840B (it) | Formulazioni orali di ubidecarenone in forma di capsule | |
| TNSN97134A1 (fr) | Comprime de maleate de trimebutine pellicule | |
| EP1344523A1 (fr) | Solution d'ibuprofène pour gèlules | |
| WO1999008666A3 (fr) | Composition pharmaceutique | |
| NZ331051A (en) | Instant release forms of gelled active substances | |
| EP1741344A3 (fr) | Procédé de fabrication de chewing-gum contenant un mélange de sorbitol liquide/mannitol/glycerine | |
| AU1452402A (en) | Novel pharmaceutical formulation in the form of cellulose capsules suitable for benzimidazole derivatives | |
| US5626872A (en) | Pharmaceutical soft capsules containing lysine clonixinate and a process for their preparation | |
| JPS6440423A (en) | Patch for mucosa in oral cavity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20150223 |